November 8, 2018 – By Vivian Park
Analysts expect MediWound Ltd. (NASDAQ: MDWD) to report -0.19 USD on November 15. They anticipate 0.03 USD changes in the EPS or 18.75% from 0.16 USD for the last quarter. After an earlier download of -0.15 USD per EPS, analysts from MediWound Ltd. record a 26.67% increase in EPS. Shares fell 0.17% or 0.01 USD during the last session, to 5.79 USD. About 31,842 shares on the market or 17.18% more than the average. MediWound Ltd. (NASDAQ: MDWD) increased by 13.04% from November 8, 2017. And it notes increases. It has achieved less than 2.58% of S & P500.
MediWound Ltd. (NASDAQ: MDWD) Rating Coverage
Among the two analysts dealing with Mediwound (NASDAQ: MDWD), 2 have a Buy rating, 0 Sell and 0 Pause. That's why 100% is positive. Mediwound had 3 analyst reports from May 10, 2018 according to SRatingsIntel. Resource MediWound Ltd. (NASDAQ: MDWD) has the "Buy" rating granted on Thursday, May 10 by Oppenheimer. Oppenheimer maintained him with the rating "Buy" and 1,400 USD on Monday, June 11 report.
MediWound Ltd., an integrated biopharmaceutical company, focuses on the development, production and commercialization of new therapeutic products in Israel. The company has a market limit of USD 157.37 million. Sells NexoBrid, a biopharmaceutical product to remove scabs, dead or damaged tissue in adults with deep thermal burns of total and full thickness. He currently has negative earnings. The company is also developing EscharEx, which is in Phase II clinical trials to clean up chronic wounds and other difficult to heal wounds.
The next current and important news from MediWound Ltd. (NASDAQ: MDWD) was published by Nasdaq.com, which published an article entitled: "MediWound to Host Third Quarter 2018 Financial Results Call November 13 at 8:30 ET" on November 7, 2018 .
Receive messages and ratings by email – Enter your email address below to receive a concise, daily summary of the latest analytics news and assessments using our FREE, daily e-mail newsletter.
By Vivian Park